• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation
Atrial fibrillation is one of the most common arrhythmias in the United States and is associated with an increased risk of thromboembolic events.1 The American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines recommend oral anticoagulation with either warfarin or oral non-vitamin K antagonists for patients diagnosed with atrial fibrillation with a high risk for ischemic stroke based on the CHA2DS2-VASc score.2 The recently published article “Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation” discussed the efficacy of...
Source: The American Journal of Cardiology - October 7, 2022 Category: Cardiology Authors: Marwa S.H. Abrahim, Olufemi Sofola-James, Zeina Bani Hani Source Type: research

Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Atrial fibrillation (AF) constitutes the most common, major cardiac arrhythmia worldwide, with an estimated prevalence in the United States equal to 2.3 million affected subjects, projected to increase to 5.6 million by 2050.1 Hypertension and background heart disease (mainly, congestive heart failure) or valve disease represent main risk factors for AF development.1 Other modifiable risk factors are sedentary lifestyle, smoking, obesity, diabetes mellitus, and obstructive sleep apnea.2 AF is associated with a significant increase in the risk for all-cause and cardiovascular death, ischemic stroke, heart failure (HF), isch...
Source: The American Journal of Cardiology - August 13, 2021 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, Michael Doumas Source Type: research

Meta-Analysis of Racial Disparity in Utilization of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is the most common arrhythmia in the United States (US), and is associated with a substantial increase in the risk of ischemic stroke. Although prevalence of AF is lower in black individuals, they face a higher risk of stroke compared with patients of white race.1 Oral anticoagulant (OAC) therapy is the stroke prevention strategy in high-risk patients with AF. Despite the higher burden of ischemic stroke in Black AF patients, some studies suggest lower utilization of OAC among them.
Source: The American Journal of Cardiology - June 17, 2021 Category: Cardiology Authors: Izza Shahid, Muhammad Shariq Usman, Tariq Jamal Siddiqi, Faiza Zakaria, Mohamad Alkhouli Source Type: research